William E Russell
Overview
Explore the profile of William E Russell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1867
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jacobsen L, Cuthbertson D, Bundy B, Atkinson M, Moore W, Haller M, et al.
Diabetes Care
. 2024 Apr;
47(6):1048-1055.
PMID: 38621411
Objective: Mixed-meal tolerance test-stimulated area under the curve (AUC) C-peptide at 12-24 months represents the primary end point for nearly all intervention trials seeking to preserve β-cell function in recent-onset...
2.
Virostko J, Wright J, Williams J, Hilmes M, Triolo T, Broncucia H, et al.
Diabetes Care
. 2023 Dec;
47(3):393-400.
PMID: 38151474
Objective: This multicenter prospective cohort study compared pancreas volume as assessed by MRI, metabolic scores derived from oral glucose tolerance testing (OGTT), and a combination of pancreas volume and metabolic...
3.
Russell W, Moore D, Herold K
Diabetes Care
. 2023 Oct;
46(11):e210-e211.
PMID: 37890101
No abstract available.
4.
Russell W, Bundy B, Anderson M, Cooney L, Gitelman S, Goland R, et al.
Diabetes Care
. 2023 Mar;
46(5):1005-1013.
PMID: 36920087
Objective: Previous studies showed that inhibiting lymphocyte costimulation reduces declining β-cell function in individuals newly diagnosed with type 1 diabetes. We tested whether abatacept would delay or prevent progression of...
5.
Kinney M, You L, Sims E, Wherrett D, Schatz D, Lord S, et al.
J Endocr Soc
. 2023 Feb;
7(3):bvad003.
PMID: 36741943
Context: Participants with stage 1 or 2 type 1 diabetes (T1D) qualify for prevention trials, but factors involved in screening for such trials are largely unknown. Objective: To identify factors...
6.
Sigurdson S, Roden A, Marom E, Szolkowska M, Girard N, Rajan A, et al.
Mediastinum
. 2022 Feb;
3:41.
PMID: 35118267
No abstract available.
7.
Greenbaum C, Serti E, Lambert K, Weiner L, Kanaparthi S, Lord S, et al.
JCI Insight
. 2021 Nov;
6(21).
PMID: 34747368
BackgroundIL-6 receptor (IL-6R) signaling drives development of T cell populations important to type 1 diabetes pathogenesis. We evaluated whether blockade of IL-6R with monoclonal antibody tocilizumab would slow loss of...
8.
Williams J, Hilmes M, Archer B, Dulaney A, Du L, Kang H, et al.
Sci Rep
. 2020 Mar;
10(1):4767.
PMID: 32179809
Reduced pancreas volume, as measured by non-contrast magnetic resonance imaging (MRI), is observed in individuals with newly-diagnosed type 1 diabetes (T1D) and declines over the first year after diagnosis. In...
9.
Dei-Tutu S, Manful A, Heimburger D, Malechi H, Moore D, Oppong S, et al.
BMC Pediatr
. 2020 Jan;
20(1):26.
PMID: 31964362
Background: Congenital hypothyroidism is a common, yet easily treatable cause of poor growth and intellectual disability. Newborn screening programs play an important role in the early detection and treatment of...
10.
Jacobsen L, Bocchino L, Evans-Molina C, DiMeglio L, Goland R, Wilson D, et al.
Diabetologia
. 2019 Nov;
63(3):588-596.
PMID: 31768570
Aims/hypothesis: Young children who develop multiple autoantibodies (mAbs) are at very high risk for type 1 diabetes. We assessed whether a population with mAbs detected by screening is also at...